Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director · CEO, President | March 24, 2026 | March 27, 2026 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | CFO and Treasurer | April 20, 2018 | April 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gain Therapeutics, Inc.
Report date March 24, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-03-24 | Direct | 200,000 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
SELLAS Life Sciences Group, Inc.
Report date April 20, 2018 · Filed April 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2028-04-19 | Direct | 40,000 |
Reported balance
After 2018-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-20 · Grant · Acquired 40,000 · Balance 40,000 F1: One-quarter (1/4) of the option shares will vest and became exercisable one year from the April 20, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-quarter (1/4) of the option shares will vest and became exercisable one year from the April 20, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 27, 2026 00:01 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001104659-26-035403 · tm269848-2_4seq1.xml · derivative · entry 1 Mack Gene · CIK 0001737979 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 20, 2025 Filed Mar 22, 2025 00:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001493152-25-011175 · ownership.xml · derivative · entry 1 Mack Gene · CIK 0001737979 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: The shares underlying the option shall vest as to 25% on March 20, 2026, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 02:00 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 271,325 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001493152-25-001281 · ownership.xml · derivative · entry 1 Mack Gene · CIK 0001737979 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,325 Underlying: Common Stock · 271,325 shares Expires 2035-01-06 F1 · derivative.exercise_date: The shares underlying the option shall vest as to 25% on January 6, 2026 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 21:23 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | PurchaseCommon Stock | 14,400 | $1.01 | $14,544.00 |
DisclosureSEC source: 0001493152-24-031378 · ownership.xml · nonDerivative · entry 1 Mack Gene · CIK 0001737979 · CFO and Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.98 to $1.07 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 23:44 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001493152-24-013983 · ownership.xml · derivative · entry 1 Mack Gene · CIK 0001737979 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-04-08 F1 · derivative.exercise_date: The shares underlying the option shall vest 25% on April 8, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:53 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001209191-18-025967 · doc4.xml · derivative · entry 1 Mack Gene · CIK 0001737979 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-04-19 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the April 20, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.